SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. SphingoTec GmbH was established in 2002 by Dr. Andreas Bergmann was one of the founders of B.R.A.H.M.S. AG. As former Chief Research Officer, he was responsible for the development of the “gold standard” sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).
| Website | http://www.sphingotec.com |
| Employees | 19 (13 on RocketReach) |
| Founded | 2002 |
| Address | Neuendorfstraße, 15A, Hennigsdorf, Brandenburg 16761, DE |
| Industry | Biotechnology Research |
| Keywords | Biomarker Discovery, Diagnostic Biomarkers, Biomarker Development, Early Disease Detection, Innovative Diagnostics, Medical Diagnostics, Critical Care Diagnostics, Point Of Care Diagnostics, In Vitro Diagnostics, Diagnostics Technology, Clinical Diagnostics, Health Diagnostics |
| Competitors | Siemens Healthineers, Roche, Thermo Fisher Scientific, Abbott, Agilent Technologies, Hologic, Inc., bioMérieux, PerkinElmer, Inc., QuidelOrtho, Ortho Clinical Diagnostics - ANZ +37 more (view full list) |
Looking for a particular SphingoTec employee's phone or email?
Deborah Bergmann is the Managing Director and CEO of SphingoTec.
13 people are employed at SphingoTec.
SphingoTec is based in Hennigsdorf, Brandenburg.